SOBRE-EXPRESIÓN DE LA PROTEÍNA
P53 EN LA DISPLASIA CERVICAL
ESTUDIO INMUNOHISTOQUÍMICO EN 55 CASOS DEL HOSPITAL
REGIONAL DE APOYO DE ICA.
BIBLIOGRAFÍA
Bernardini S., Adessi G., Billerey C.,
ChezyE.,Carbillet J.,Bittard H. 1999. Immunohistochemical detection of p53 protein
overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 162:1496.
Esrig D., Spruck C., Nichols P.,
Chaiwun B., Steven K., Grohen S., Chen S., Skinner D., Jones P., Cote R. 1993. p53 nuclear
protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in
bladder cancer. Am J Pathol 143: 1389.
Malcolm EK.,Baber GB.,Boyd JC.,Stoler
MH. 2000. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod
Pathol 13(4): 373 - 378.
Risinger JI., Geargette AD.,
Ignar-Trowbridge D., Malachlan JA., Tsao M., Senterman M., Boyd J. 1992. p53 gene
mutations in human endometrial carcinoma. Mol Carcinog 5: 250 - 253.
Sarkis A., Dalvagni G., Cordon-Cardo
C., Zhang Z., Sheinfeld J., Fair W., Herr H., Reuter V. 1993. Nuclear overexpression of
p53 in transitional cell carcinoma: a marker for disease progression. J Natl Cancer Inst
85: 53.
Tenti P., Vesentini N., Rondo S.,
Zappatore R., Migliora P., Carnevali L., Ranzani G. 2000. Can Epid Biomar 9(4): 435 - 438.
Uchida T., Wada C., Ishida H., Wang C.,
Egawa S., Yokoyama E., Kameya T., Koshiba K. 1995. p53 mutations and prognosis in bladder
tumors. J Urol 153: 1097.
Uchiyama M., Iwasaka T., Matsuo N.,
Hachisuga T., Mori M., Sugimori H. 1997. Correlation between human papillomavirus
positivity and p53 gene overxpression in adenocarcinoma of te uterine cervix 65: 23 - 29.
Velculescu V, El-Deiry W. 1996.
Biological and clinical iniportance of the p53 tumor suppressor gene. Clin Chem. 42: 858.
Wynford-Thomas D. 1992. Can we trust
immunocytochemistry- J Pathol 166:329 -330.
Regresar
|
